Skip to main content
Cartesian Therapeutics, Inc. logo

Cartesian Therapeutics, Inc. — Investor Relations & Filings

Ticker · RNAC ISIN · US8162121045 US Manufacturing
Filings indexed 852 across all filing types
Latest filing 2025-05-08 Interim / Quarterly Rep…
Country US United States of America
Listing US RNAC

About Cartesian Therapeutics, Inc.

https://www.cartesiantherapeutics.com/

Cartesian Therapeutics, Inc. is a clinical-stage company that pioneers the development of mRNA-engineered cell therapies. The company's primary focus is on creating treatments for autoimmune diseases. Leveraging its novel mRNA technology platform, Cartesian develops therapeutic cells designed to target the drivers of these conditions. This approach aims to expand the reach and potential of cell therapy for patients with various autoimmune disorders. The company's lead asset, Descartes-08, is a central component of its clinical pipeline.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2025
2025-05-08 English
8-K
Regulatory Filings
2025-05-08 English
8-K
Regulatory Filings
2025-04-29 English
DEF 14A
Proxy Solicitation & Information Statement
2025-04-28 English
DEFA14A
Regulatory Filings
2025-04-28 English
FORM 4
Director's Dealing
2025-04-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.